Monoacylglycerol lipase (MAGL) is a serine hydrolase that plays an important role in the degradation of the endocannabinoid neurotransmitter 2-arachidonoylglycerol, which is implicated in many physiological processes. Beyond the possible utilization of MAGL inhibitors as antiinflammatory, anti-nociceptive and anti-cancer agents, their application has encountered obstacles due to the unwanted effects caused by the irreversible inhibition of this enzyme. The possible application of reversible MAGL inhibitors has only recently been explored, mainly due to the deficiency of known compounds possessing efficient reversible inhibitory activities. In this work, we report a new series of reversible MAGL inhibitors. Among them, compound 26 showed to be a potent MAGL inhibitor (IC 50 = 0.51 µM, K i = 412 nM) with a good selectivity versus fatty acid amide hydrolase (FAAH), α/β-hydrolase domain-containing 6 (ABHD6) and 12 (ABHD12).
compound 1 (Figure 1 ) was reported as a MAGL inhibitor with relatively low potency (IC 50 = 28 µM) 18 and it was shown to be equally potent against FAAH in vitro. 19, 20 Furthermore, its administration was shown to attenuate nociception in rodent models of acute, inflammatory, and neuropathic pain. 21, 22 Compound 2 ( Figure 1 ) is an irreversible MAGL inhibitor (IC 50 = 140 nM)
that was found to decrease 2-AG hydrolase activity of rat cerebellar membranes. 23 NAM is not selective due to its chemically reactive maleimide functional group that will likely react with many cysteine-containing proteins in vivo, thus limiting its use in physiologic studies. Another carbamate-based derivative 3 (OMDM169, Figure 1 ) is a MAGL competitive inhibitor (IC 50 = 0.89 µM) 24 that increased the 2-AG levels at the site of formalin-induced paw inflammation but it also inhibited pancreatic lipase and DAGL-α, because of its structural similarity with tetrahydrolipstatin.
Selective pharmacological tools able to interrupt the in vivo MAGL activity have only become accessible within the last few years. By now, they have been used to demonstrate the role of this enzyme in 2-AG signaling termination and the potential translational use of targeting MAGL in the treatment of nervous system disorders such as pain, anxiety, drug addiction, nausea, and neuroinflammation. [25] [26] [27] Furthermore, MAGL is upregulated in aggressive cancer cells and primary tumors and its inhibition in aggressive breast, ovarian and melanoma cancer cells impairs cell migration, invasiveness and tumorigenicity. 28 Confirmation of MAGL as the primary brain 2-AG hydrolase was achieved by the generation of a selective and in vivo active MAGL inhibitor, JZL184
(4, Figure 1 ). This piperidine carbamate is a potent and selective MAGL inhibitor (IC 50 = 8 nM)
that when administered to mice, elevated brain 2-AG levels leading to several cannabinoid-related behavioral effects. 29 Almost all the reported compounds are characterized by an irreversible MAGL inhibition mechanism and as reported by Scholsburg et al., the irreversible inhibition of MAGL produces cross-tolerance to CB 1 agonists in mice after repeated administrations. 30 Furthermore, 5 chronic MAGL blockade causes physical dependence, impairs endocannabinoid-dependent synaptic plasticity and desensitizes brain CB 1 receptors. 30 Considering these drawbacks associated with an irreversible MAGL inhibition, the development of reversible inhibitors could represent a promising alternative strategy; however, their use has been investigated only partially so far, mainly because of the lack of compounds with good MAGL reversible inhibition properties. In 2012 Cisneros et al.
reported a series of oxirane derivatives characterized by a dual MAGL/FAAH reversible inhibition activity; 31 Interestingly, this compound was also tested in vivo and its therapeutic effects were not accompanied by catalepsy or other motor impairments that have been observed instead after the administration of irreversible MAGL inhibitors. 32 In 2015 In the present study, we report the development of a diphenylpyrazole series as a new class of MAGL reversible inhibitors.
RESULTS AND DISCUSSION
From the analysis of the main available data concerning MAGL reversible inhibition, [34] [35] [36] some pharmacophoric elements seem to be important for inhibitory activity: a) a carbonyl group able to interact into the oxyanion hole of the enzyme, b) an aromatic portion comprising also an heterocyclic nucleus, involved in van der Waals interactions in a closed hydrophobic region of the binding site (red region of Figure S1 ) and c) a second aromatic portion which interacts in the open large hydrophobic cavity of MAGL (green region of Figure S1 ). Following this binding analysis, we hypothesized that the 1,5-diphenylpyrazole scaffold, properly substituted with a carbonyl group and different fragments, could represent the starting point for the identification of new reversible MAGL inhibitors. Following these indications, we synthesized three different diphenylpyrazole derivatives (6-8, Table 1 ) characterized by different substituents. The compounds were thus tested for their MAGL inhibition activity together with the CAY10499 derivative, 37 which was used as a 7 reference compound. As shown in Table 1 , the (5-(4-hydroxyphenyl)-1-phenyl-1H-pyrazol-3-yl)(4-(pyrimidin-2-yl)piperazin-1-yl)methanone (8) showed an appreciable activity with an IC 50 value of 6.8 µM, whereas the other two compounds were inactive. Using this compound as a starting hit, a first round of structural investigation has been carried out by maintaining the central pyrazole core fixed and varying: 1) the substituent present on the nitrogen atom (phenyl or methyl group) of the pyrazole ring (R 2 , Table 2 ); 2) the portion linked to the carbonyl group in position 3 of the pyrazole ring (R 3 , Table 2 ) and 3) the position of the hydroxyl group of the phenolic ring in position 5 (R 1 , Table 2 ). As shown in Table 2 , the substitution of the 1-phenyl ring with a methyl group determined an important decrease of activity (compound 9) compared to 8, as well as the shift of the p-hydroxy group to the meta position (compound 10). The replacement of the pyrimidine with a phenyl ring determined a slight increase of activity (11, IC 50 = 4.7 µM), but when a benzyl group was inserted in place of the phenyl the activity was about two-fold lower (14, IC 50 = 12 µM). When pyrimidine was replaced with a methyl group (12) or the entire piperazinylpyrimidine fragment with a morpholine ring (13) a ten-fold decrease of activity was observed. Conversely, the best result was achieved by the replacement of the piperazinylpyrimidine with the 4-benzylpiperidine, which led to a 3.5 fold increase of the activity (15, IC 50 = 2.0 µM). Finally, the replacement of the 4-benzylpiperidine with larger 9 dimension groups such as the 1-benzylpiperidin-4-amine of compound 16 and the 2-(4-(pyrimidin-2-yl)piperazin-1-yl)ethanamine of compound 17 led to a completely loss of activity. As shown in Figure 3 , with respect to the piperazinylpirimidine of derivative 8, the 4- In order to verify the role of the p-hydroxyl in the binding process, this group was removed or replaced with a chlorine atom. As shown in On these bases, the phenyl ring of 15 was substituted with different groups, such as the p-methoxy (20) , p-chloro (21) and p-methyl (22) and with different aromatic portions such as the benzyl (23), phenylethyl (24) and phenylpropyl (25) fragments. The enzymatic assays revealed that the introduction of the benzyl group such as in compound 23 determined the highest increase of inhibitory activity (IC 50 = 0.81 µM, Table 3 ). Then, in order to maximize the lipophilic interactions of this fragment, methyl groups in para and meta position of the benzyl moiety were introduced (26, 27 and 28). Finally, a naphtylmethyl group (29) was inserted in the place of the benzyl group.
As shown in Table 3 , the meta-methyl substitution of the benzyl ring determined a further slight improvement of the MAGL inhibitory activity, with a resulting IC 50 of 0.51 µM (compound 26). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 As shown in Figure 4 , the binding disposition of compound 26 is very similar to that observed for 15, maintaining the lipophilic interactions of the 4-benzylpiperidine with L184, V270 and the π-π interaction with Y194, the interaction of the carbonyl group in the oxyanion hole and the H-bond between the p-hydroxyl group and the oxygen backbone of P178. Differently from 15, the mmethylbenzyl fragment points towards the surface of the binding site and shows stronger lipophilic interactions with in particular A151 and L241. With the aim of evaluating the reversible or irreversible mechanism of inhibition, the effects of dilution and preincubation on the inhibitory ability of compound 26 were evaluated. In the dilution experiments, in case of an irreversible inhibition, the potency should not decrease after dilution.
Differently, in case of a reversible inhibition, the potency level should be substantially reduced after dilution. 38 In our experiment, the inhibition produced by preincubation with a 20 µM concentration of 26 was measured after a 40X dilution and compared to the potency observed by a 20 µM and a 0.5 µM of compound 26. As shown in Figure 5A , 26 showed a reversible inhibition mechanism, as the inhibition produced by 0.5 µM of the compound was similar to that of 40X dilution, and was different to that produced by the compound at a concentration of 20 µM. As a second test, the activity of 26 was assayed at different preincubation times of the compound with MAGL. In this assay, the compound is incubated with the enzyme 30 and 60 minutes before the addition of the substrate and the observed IC 50 is then compared with that obtained without a preincubation of the compound with the enzyme. An irreversible inhibitor will show a higher potency with a higher incubation time whereas a reversible inhibitor will show a constant inhibition potency independent from the incubation time. As shown in Figure 5B , this assay confirmed the reversible property of 26, as it did not show any significant increase in inhibition potency with different incubation times. Once confirmed the reversible mechanism of compound 26, its inhibition mode was then determined by evaluating Michaelis-Menten kinetics with various inhibitor concentrations. The were tested. As shown in Table 4 , compound 26 did not show any significant inhibition of FAAH and ABHD12 at the concentration of 10 µM (7% and 32% of inhibition for FAAH and ABHD12, Table 4 this compound did not show a significant binding to any of the two cannabinoid receptor subtypes. or the cell cycle pathway (OVSAHO, COV318, OVCAR3), which are common events in HG-SOC.
Therefore, the antiproliferative activity of the two compounds was tested against these four cell lines, together with the noncancerous human fibroblast lung cells (MRC5). As shown in showed a complete pain relief. These results highlight: i) the long lasting efficacy of the compound after repeated treatments, ii) the increasing activity during treatment, suggesting protective properties against oxaliplatin neurotoxicity, iii) the complete lack of tolerance development. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 20 compared to oxaliplatin-treated mice (see Figure S2 ). Previous studies reported that covalent MAGL inhibitors exert significant anti-allodynic effects in different mouse models of neuropathic pain. [41] [42] [43] [44] However, in these animal models MAGL inhibition exerted opposite effects on the modulation of 2-AG concentrations in brain, spinal cord and dorsal root ganglia (DRGs). For example, Kinsey at al. reported a marked increase of 2-AG levels in brain and spinal cord of mice treated with a single injection of JZL184 (16 mg/kg, ip) 14 days after chronic constriction injury (CCI) surgery. 41 On the contrary, Khasabova et al. reported no significant change in 2-AG levels in brain and spinal cord after 7 days of treatment with cisplatin and JZL184 (10 µg, subcutaneous injection). 45 In the same study, JZL184 was able to recover the cisplatin-induced reduction of 2-AG level in DRGs. Wilkerson et al. showed that suprathreshold dose of MJN110 (0.1432 mg/kg, ip)
could only marginally increase 2-AG level in the spinal cord of mice subjected to CCI surgery while not affecting 2-AG level in the brain. 44 Our data showed that compound 26 did not increase 2-AG levels in brain and spinal cord of mice treated for 15 days, despite inducing significant antiallodynic effects. This may be due to a mild and specific increase of 2-AG concentrations in specific brain or spine regions. Alternatively, compound 26 may exhibit only a negligible penetration or activity in the central nervous system. Previous studies showed that the anti-allodynic effect of FAAH and MAGL inhibitors is associated with the modulation of AEA and 2-AG levels in DRGs. 45, 46 Thus, we may speculate that the anti-allodynic effect induced by compound 26 could be associated with the modulation of 2-AG levels in the peripheral nervous system (i.e. DRGs). In agreement with this hypothesis, it was shown that the disposition of cisplatin is limited to peripheral tissues and DRGs were the most vulnerable neural structure. 47 However, we cannot exclude the possibility that the in vivo effects showed by compound 26 may also be dependent by alternative mechanisms beyond MAGL inhibition.
Chemistry. The diphenylpyrazole compounds 6-29 were prepared as shown in Scheme 
CONCLUSIONS
In the present work we have reported a new class of MAGL reversible inhibitors. Starting from (5- (8) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 23 it TM software and compound 26 was thus filtered by using this program. The result highlighted that this compound did not possess any of the substructural features shared by the most common PAINS.
Interference analysis. Some PAINS are associated with color that could interfere photometrically with the assay. In order to avoid this possibility for each compound concentration a blank analysis was carried out, and the final absorbance values were obtained subtracting the absorbance determined by the presence of all the components except the enzyme in the same conditions.
Aggregation analysis. In order to exclude possible aggregation behaviors, all the enzymatic assays were carried out in the presence of bovine serum albumin (BSA) 0.1 mg/ml.
Thiol reactive analysis.
In some cases, PAINS properties could be caused by a covalent interaction between a ligand and cysteines of multiple proteins. 53 In order to investigate this possibility, the inhibition activity of 26 against MAGL was tested in the presence of the thiol-containing agent 1,4-dithio-DL-threitol (DTT). 54 This assay suggested that the inhibition potency of 26 was not affected by the presence of DTT, as it showed an IC 50 = 0.50 ± 0.04 µM when assayed with 100 µM DTT, thus excluding the interaction of this compound with the cysteine residues of the MAGL enzyme. 55 a selectivity analysis is another test that would contribute to highlight most PAINS. As reported in the text we measured the activity of compound 26 against FAAH, ABHD6 and ABHD12 resulting in a good MAGL selectivity.
Selectivity testing. As reported by Dahlin and Walters
Orthogonal assay. The application of a different readout method for measuring the activity against the target is another step that contribute to elucidate the PAINS properties. For this reason the activity of 26 against MAGL was also tested by using an HPLC/UV assay. 56 An aliquot of stock 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Docking Calculations. The crystal structure of human MAGL (pdb code 3PE6 35 ) was minimized using Amber14 software 57 and ff14SB force field at 300 K. The TIP3P explicit solvent model for water, was used with a 10 Å water cap. In order to neutralize the system, sodium ions were added.
Two minimization steps of were performed; in the first stage, the protein was kept fixed with a position restraint of 500 kcal/mol Å 2 minimizing the positions of the water molecules. In the second stage, the entire system was minimized through 5000 steps of steepest descent followed by conjugate gradient (CG) until a convergence of 0.05 kcal/Å•mol. The ligands were built using Maestro 58 and were minimized by means of Macromodel 59 in a water environment using the CG method using the MMFFs force field. Docking analysis was performed by means of the binding.
ABHD6 and ABHD12 inhibition assay.
ABHDs activity assays were performed as previously described. 8 The hABHD6 and hABHD12 activity was determined using cell homogenates from Cell viability assay. OVSAHO, OVCAR3, COV318, CAOV3 and MRC5 (from ATCC) were maintained at 37 °C in a humidified atmosphere containing 5% CO 2 accordingly to the supplier.
Normal (1.5 × 10 4 ) and tumor (5 × 10 2 ) cells were plated in 96-well culture plates. The day after seeding, vehicle or compounds were added at different concentrations to the medium. Compounds were added to the cell culture at a concentration ranging from 100 to 0.01 µM. Cell viability was measured after 96 h according to the supplier (Promega, G7571) with a Tecan F200 instrument.
IC 50 values were calculated from logistical dose response curves. Averages were obtained from three independent experiments, and error bars are standard deviations (n = 3). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 29 of variance of behavioral data was performed by one way ANOVA, a Bonferroni's significant difference procedure was used as post-hoc comparison. P values of less than 0.05 or 0.01 were considered significant. Investigators were blind to all experimental procedures. Data were analyzed using the "Origin 9" software (OriginLab, Northampton, USA). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 30 mL/min. The different method was used since 9 was the only target compound bearing an alkyl group (a methyl group) as R 2 substituent (Table 2) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Animals

General Procedures and
5-(4-Hydroxyphenyl)-1-(2-phenylethyl)-1H-pyrazole-3-carboxylic acid (31h
5-(4-Hydroxyphenyl)-1-((naphthalen-1-yl)methyl)-1H-pyrazole-3-carboxylic acid (31m).
ASSOCIATED CONTENT
Supporting Information
The Supporting Information is available free of charge on the ACS Publications website at DOI:
XXXX. 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 TABLE OF 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
